Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients (IGNORANT)

Civil Hospices of Lyon

Status and phase: Enrolling; Phase 3

Conditions: Pneumonia, Ventilator-Associated

Treatments: Drug: Placebo; Drug: Interferon gamma

Study type: Interventional

Funder types: Other

Identifiers

NCT05843786

2022-502229-16-00 (Other Identifier)

69HCL22_0851

Details and patient eligibility

About

Clinical presentation of patients after severe injury such as a severe infection, trauma or extensive burns is characterized by the simultaneous occurrence of dysregulation of the initial inflammatory response and immunosuppression associating quantitative and functional alterations of innate and adaptive immune cells. These acquired immune dysfunctions have been associated with an increased susceptibility to nosocomial infections, foremost among which are ventilator-associated pneumonia (VAP). Despite the implementation of a set of preventive measures, the incidence of these VAP remains high in intensive care, with rates in Europe of 1.5% per day of ventilation.

Post-aggressive immunosuppression is characterized by the decrease in the expression of HLA-DR (belonging to the type II major histocompatibility complex, MHC-II) on the surface of monocytes (mHLA-DR). The administration of interferon gamma (IFNγ) can restore the level of mHLA-DR and may possibly improve the prognosis as an adjuvant therapy associated to antibiotics. However, the level of proof of this therapeutic strategy is low, limited to small cohorts of patients, or clinical studies without prior immunodepression assessment. The objective of this study is to conduct a randomized, double-blind, placebo-controlled superiority trial to assess the effect of IFNγ administration on the duration of mechanical ventilation following the first episode of VAP in patients having an HLA-DR < 8000 AB/C

All reported data about recombinant human IFNγ 1b for the control of secondary infections in patients with septic shock used the dose of 100 micrograms per day by subcutaneous route for 3 to 5 days . At this dose, no retrospective study has reported any serious adverse effects and recombinant human IFNγ 1b allows an increase in monocyte membrane expression of mHLA-DR.

Enrollment: 132 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• adult patients hospitalized in intensive care unit
• under mechanical ventilation for more than 5 days
• having a first episode of VAP (with a Clinical Pulmonary Infectious Score (CPIS score) >6)
• treated with antibiotics for less than 24 hours
• with monocyte HLA-DR < 8000 AB/C
• written informed consent signed by the patient's trusted support person, or in the absence of the patient's representative and taking into account the agreement of the relative obtained by telephone emergency certificate completed and signed by the investigator
• membership of a social security scheme

Exclusion criteria

• inability to administer the first dose of treatment in the study within 48 hours of the start of antibiotic therapy (antibiotic therapy for VAP)

• Noradrenaline > 0.25 mcg/kg/min

• Immunosuppression, defined by:

  • solid tumor with chemotherapy in the last 3 months
  • progressive metastatic disease
  • hematological disease
  • solid organ transplantation
  • HIV infection (AIDS stage or not)
  • corticosteroid therapy at any dose for more than 3 months
  • ≥ 1 mg/kg of Prednisone equivalent for more than 7 days
  • immunosuppressive therapy

• Head and/or cervical spine trauma : with a predictable impact on the duration of mechanical ventilation (left to the investigator's judgement), the investigator will assess whether the patient meets the following neurological criteria for extubation during their recovery:

• A level of consciousness assessed as 0 or 1 on the Richmond Agitation-Sedation Scale (RASS)

• FiO2 <40%

• PEEP level <5 cmH2O

• A FR/Vt ratio <105

• Effective cough

• Response to simple commands

• Administration of noradrenaline < 0.2 mcg/kg/min

• Cardiocirculatory arrest

• Burn patient

• Cirrhosis with Child B or C score

• Infection with Aspergillus spp.

• Refusal to participate

• Patient participating in another interventional research in progress or including an exclusion period still in progress at pre-inclusion (excluding interventional research of 2° not interfering with the endpoints of the study according to the judgment of the principal investigator)

• Lack of social coverage

• Patient under curatorship or guardianship

• Pregnant or breastfeeding women

• Patient admitted to intensive care for SARS-Cov2 pneumonia

• Known allergy to latex

• Hypersensitivity to the active substance (interferon gamma-1b) or known hypersensitivity to related products, such as another interferon, or to any of the following excipients: Mannitol, Disodium succinate hexahydrate, Succinic acid, polysorbate 20

• Existence of chronic heart disease with FeVG<45%

• Major hepatic impairment (total bilirubin>60 mg/L or 102 mcmol/L, equivalent to 3 SOFA points)

• thrombocytopenia <50000/mm3 (equivalent to 3 SOFA points) AST and/or ALT > 5N Lipase > 3N Severe chronic renal failure (creatinine clearance MDRD< 10 ml/min/1.73m2)

• Thrombocytopenia <50,000/mm3 (equivalent to 3 SOFA points)

• Respiratory failure requiring home oxygen therapy

• Persons under court protection

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

132 participants in 2 patient groups, including a placebo group

Interferon gamma treatment

Experimental group

Description:

Interferon gamma treatment (100 micrograms /day during 5 days)

Treatment:

Drug: Interferon gamma

Placebo

Placebo Comparator group

Description:

The comparator drug (placebo) is an injectable solution of sodium chloride 0.9%

Treatment:

Drug: Placebo